ArticleCancer research and treatment2015
Identification of EGFR Mutations by Immunohistochemistry with EGFR Mutation-Specific Antibodies in Biopsy and Resection Specimens from Pulmonary Adenocarcinoma.
Article in Cancer research and treatment, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review.Molecular biology reports · 2021Pooled it
- Patterns and risk factors of intracranial recurrence after surgical resection of brain metastases from malignant tumors.American journal of cancer research · 2025Article
- SH3 domain‑binding glutamic acid‑rich protein‑like 3 is associated with hyperglycemia and a poor outcome in Epstein‑Barr virus‑negative gastric carcinoma.Oncology letters · 2025Article
- Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer.Cells · 2024Article
- Non-Small Cell Lung Cancer: Targetable Variants in Concurrent Tissue and Liquid Biopsy Testing in a North Indian Cohort.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- MEK Is a Potential Indirect Target in Subtypes of Head and Neck Cancers.International journal of molecular sciences · 2023Article
- Article
- Computed tomography-guided lung biopsy for molecular tests: a meta-analysis.Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery · 2022Article
- Prognostic factors for recurrence in patients with surgically resected non-small cell lung cancer.Contemporary oncology (Poznan, Poland) · 2022Article
- AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing.Nature communications · 2021Article
- Role of EGFR and HER-2/NEU Expression in Gall Bladder Carcinoma (GBC).Journal of laboratory physicians · 2021Article
- Immunohistochemical Expression of Epidermal Growth Factor Receptor in Astrocytic Tumors in Iraqi Patients.Open access Macedonian journal of medical sciences · 2019Article
- Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study.World journal of oncology · 2019Article
- Article
- Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets.Cancers · 2019Article
- EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry.BMC pulmonary medicine · 2018Article
- Serum peptide expression and treatment responses in patients with advanced non-small-cell lung cancer.Oncology letters · 2018Article
- Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?Cancers · 2018Review
- Detection of epidermal growth factor receptor mutations in lung adenocarcinoma cytological specimens by immunocytochemistry.Molecular and clinical oncology · 2017Article
- Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer.Journal of breast cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMutation-specific antibodies have recently been developed for identification of epidermal growth factor receptor (EGFR) mutations by immunohistochemistry (IHC). This study was designed to investigate whether the type of specimen (biopsy vs. resection) would make a difference in determining mutation status by IHC, and to evaluate whether biopsies are suitable for detection of mutant EGFR protein. MATERIALS AND
methodsIHC was performed using mutation-specific antibodies for E746-A750 deletion (DEL) and L858R point mutation (L858R) in biopsies and tissue microarrays of resected tumors from 154 patients with pulmonary adenocarcinoma. Results were then compared with DNA sequencing data.
resultsMolecular-based assays detected EGFR mutations in 62 patients (40.3%), including 14 (9.1%) with DEL, and 31 (20.1%) with L858R. IHC with two mutation-specific antibodies showed a homogeneous staining pattern, and correctly identified EGFR mutation status in 89% (137/154). Overall (biopsy/resection) sensitivity, specificity, positive predictive value, and negative predictive value were 75.6% (78.3%/72.7%), 94.5% (90.9%/96.3%), 85% (78.3%/88.9%), and 90.4% (90.9%/89.7%), respectively.
conclusionOur data showed that IHC using EGFR mutation-specific antibodies is useful for detection of EGFR mutations with high specificity and good sensitivity not only for resection specimens but also for biopsy materials. Therefore, IHC using EGFR mutation-specific antibodies may preclude a second biopsy procedure to obtain additional tissues for identification of EGFR mutations by molecular assays in biopsies from advanced cancer, particularly when tumor cells in the samples are limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.